May 10, 2017
CHICAGO — Researchers found that nearly a quarter of pediatric patients who underwent liver transplantation for primary sclerosing cholangitis had recurrence posttransplant, particularly patients who were younger or had autoimmune hepatitis, according to a presentation at Digestive Disease Week.
“Liver transplantation is the only therapy for primary sclerosing cholangitis. Most liver transplant outcomes for children are generally good. Pediatric onset PSC and PSC with autoimmune hepatitis overlap phenotype are quite rare. Furthermore, pediatric liver transplant for PSC is quite uncommon,” Fateh Bazerbachi, MD, from the Mayo Clinic, Rochester, Minnesota said. “Our study objective was to characterize the current PSC as [indication for] liver transplant using a large, multicenter international cohort of children with this disease.”